[ad_1]
According to the neurologist, a positive therapy study of progressive forms of MS at the secondary-chronic stage is also interesting. "The siponimod modulator S1P slowed the progression of these in a phase 3 study specific to SPMS."
Multiple Sclerosis research is undergoing new breakthroughs. "For the first time, a biomarker in the blood has been identified, providing reliable information on the extent of neuronal damage, disease progression and response to MS treatment," said Professor Frauke Zipp , MS expert from the German Society of Neurology (DGN) and board member Network of Disease Competencies, Multiple Sclerosis (KKNMS). Zipp, who today presented current studies on the prognosis and treatment of inflammatory diseases at Neurowoche in Berlin, spoke of an "unprecedented success." According to the neurologist, a positive therapy study of progressive forms of MS at the secondary-chronic stage is also interesting. "The siponimod modulator S1P slowed the progression of these in a phase 3 study specific to SPMS."
Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system. The disease poses major challenges for physicians and patients, as it can lead to movement and cognitive impairment in young adults, and MS immunotherapy may be badociated with various complications. "The treatment of MS has been a huge success over the past two decades, but the safety of prognosis and the progression of disability remain major problems," says Frauke Zipp, director of Clinic and neurology polyclinic of the Johannes Gutenberg University of Mainz.
Neurofilament shows nerve damage
With a newly discovered biomarker in the blood serum, the severity of nerve damage can be determined easily and reliably. "Neurofilament light chain protein (NfL) is a component of the neuronal cytoskeleton that occurs in multiple sclerosis and neurodegenerative diseases in the blood, where it can now be determined by a very sensitive measurement method," explains Zipp. "While many problems remain to be resolved, we can expect NfL to be a predictive serum biomarker and a surrogate for treatment response for multiple sclerosis and neurodegeneration."
Positive therapy study with SPMS
There is also hope for people with secondary progressive MS secondary (SPMS). The development of a secondary progressive course is the decisive factor for the long-term prognosis. "Siponimod, a selective modulator of sphingosine-1-phosphate receptors, has been shown to be effective in the treatment of MSPS." This is the first phase 3 positive therapeutic study explicitly for SPMS with a drug of the same type. group against MS very active, "reports Zipp. Patients were initially 48 years old in the Phase 3 trial, had suffered from multiple sclerosis for about 17 years on average, had been at the SPMS stage for about four years and 56% needed aids to the market. "In these patients, on average 18 months of treatment compared to placebo, the confirmed risk of progression of disability was reduced by 21%, but the adverse effects are similar to those of fingolimod, a drug against MS. "said the neurologist. It was a fairly short period of observation, and we certainly wanted even more dramatic effects for the patients, most of them still young, says Zipp. "But it's a progress, and it's exciting."
literature
Siller N et al. The serum neurofilament light chain is a biomarker of both acute and chronic neuronal damage at the onset of multiple sclerosis. Mult Scler 2018 March 1: 1352458518765666
Khalil M et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Rev Neurol. 2018; 14 (10): 577-589
Kappos L et al. Siponimod versus placebo in progressive progressive multiple sclerosis (EXPAND): randomized double-blind phase 3 study. Lancet 2018; 391 (10127): 1263-1273. doi: 10.1016 / S0140-6736 (18) 30475-6
Press Office of the Congress of the German Society of Neurology
c / o albertZWEI Media GmbH, Oettingenstrbade 25, 80538 Munich
Phone: +49 (0) 89 46148622, Fax: +49 (0) 89 46148625
Press spokesperson: Prof. Dr. med. med. Hans-Christoph Diener, Essen
Email: [email protected]
German Society of Neurology eV (DGN)
sees itself as a neurological professional society in the sense of social responsibility, with its more than 9,000 members to provide neurological health care in Germany. To this end, DGN promotes science and research as well as education, continuing education and training in neurology. She participates in the discussion on health policies. The DGN was founded in 1907 in Dresden. The office seat is in Berlin. www.dgn.org
President: Prof. dr. med. Gereon R. Fink
Vice President: Prof. Dr. med. med. Christine Klein
Past President: Prof. Dr. med. med. Ralf Gold
Director General: Dr. med. Last. nat. Thomas Thiekötter
Office: Reinhardtstr. 27 C, 10117 Berlin, Phone: +49 (0) 30 531437930, E-Mail: [email protected]
The Multiple Sclerosis Disease Competency Network (KKNMS)
is one of 21 medical competence networks established throughout Germany by the Federal Ministry of Education and Research. They all aim to bring together researchers on specific national and interdisciplinary disease patterns to enable rapid transfer of research results into practice. Current KKNMS projects focus on the long-term improvement of MS diagnosis, treatment and care. The office is located at the Klinikum Rechts der Isar of the Technische Universität München.
www.kompetenznetz-multiplesklerose.de
scientific contact:
Teacher. Dr. med. Frauke Zipp
Director of the Neurological Clinic of the University Medical Center Mainz
Building 503 EC, Langenbeckstr. 1, 55131 Mainz
Phone: +49 (0) 6131 177156
Email: [email protected]
idw 2018/11
Source link
